Bepotastine (Bepreve) - An ophthalmic H1-antihistamine

Medical Letter on Drugs and Therapeutics

Volumn 52, Issue 1331, 2010, Pages 11-12

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALAWAY; AZELASTINE; BEPREVE; BETOTASTINE; CETIRIZINE; CROMOGLYCATE DISODIUM; DESLORATADINE; EMEDASTINE; EPINASTINE; FEXOFENADINE; KETOROLAC; KETOROLAC TROMETAMOL; KETOTIFEN; KETOTIFEN FUMARATE; LODOXAMIDE; LODOXAMIDE TROMETAMOL; LORATADINE; NEDOCROMIL; NEDOCROMIL SODIUM; OLOPATADINE; PATADAY; PEMIROLAST; PROMETHAZINE; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; EYE IRRITATION; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; RHINOPHARYNGITIS;

ADMINISTRATION, TOPICAL; ANIMALS; EYE DISEASES; HISTAMINE H1 ANTAGONISTS; HUMANS; OPHTHALMIC SOLUTIONS; PIPERIDINES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77749283547     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. L Bielory and MH Friedlaender. Allergic conjunctivitis. Immunol Allergy Clin North Am 2008; 28:43.
2. V Yaylali et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand 2003; 81:378.
3. Drugs for allergic disorders. Treat Guidel Med Lett 2010; 90:9.
4. MB Abelson et al. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther 2009; 31:1908.
5. TT Macejko et al. Bepotastine besilate ophthalmic solution 1.5% reduces ocular itching following dosing in the conjuctival allergen challenge (CAC) model of acute allergic conjunctivitis [poster]. Association for Research in Vision and Ophthalmology (AVRO) 2009 Annual Meeting; May 3-7, 2009; Fort Lauderdale, FL.
6. GL Torkildsen et al. Bepotastine besilate ophthalmic solution 1.5% reduces ocular itching in a clinical model of allergic conjunctivitis [abstract]. J Allergy Clin Immunol 2009; 123:S57.
7. EE Protzko et al. The ocular comfort and safety of the novel anti-histamine bepotastine besilate ophthalmic solution 1.5% in a healthy pediatric population [abstract]. J Allergy Clin Immunol 2009; 123:S50.